Revive Therapeutics Provides Update on FDA Type C Meeting for Clinical Study

posted Jun 13, 2024 9:00am  by  Revive Therapeutics Ltd.
“We are pleased with the FDA’s recommendations for our proposed clinical study, which provides a pathway for the clinical development of Bucillamine as a potential treatment for Long COVID,” said Michael Frank, CEO of Revive. “We aim to finalize the clinical study protocol and submit a new IND, which will cross reference our current IND to obtain FDA approval to proceed with the clinical trial for Long COVID.” ...read more